These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21628494)

  • 1. Detection of promoter hypermethylation in salivary rinses as a biomarker for head and neck squamous cell carcinoma surveillance.
    Carvalho AL; Henrique R; Jeronimo C; Nayak CS; Reddy AN; Hoque MO; Chang S; Brait M; Jiang WW; Kim MM; Claybourne Q; Goldenberg D; Khan Z; Khan T; Westra WH; Sidransky D; Koch W; Califano JA
    Clin Cancer Res; 2011 Jul; 17(14):4782-9. PubMed ID: 21628494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of TIMP3 promoter hypermethylation in salivary rinse as an independent predictor of local recurrence-free survival in head and neck cancer.
    Sun W; Zaboli D; Wang H; Liu Y; Arnaoutakis D; Khan T; Khan Z; Koch WM; Califano JA
    Clin Cancer Res; 2012 Feb; 18(4):1082-91. PubMed ID: 22228635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of promoter hypermethylation pattern in salivary rinses collected with and without an exfoliating brush from patients with HNSCC.
    Sun W; Zaboli D; Liu Y; Arnaoutakis D; Khan T; Wang H; Koch W; Khan Z; Califano JA
    PLoS One; 2012; 7(3):e33642. PubMed ID: 22438973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of promoter hypermethylation detection in body fluids as a screening/diagnosis tool for head and neck squamous cell carcinoma.
    Carvalho AL; Jeronimo C; Kim MM; Henrique R; Zhang Z; Hoque MO; Chang S; Brait M; Nayak CS; Jiang WW; Claybourne Q; Tokumaru Y; Lee J; Goldenberg D; Garrett-Mayer E; Goodman S; Moon CS; Koch W; Westra WH; Sidransky D; Califano JA
    Clin Cancer Res; 2008 Jan; 14(1):97-107. PubMed ID: 18172258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of TIMP3 hypermethylation in post-treatment salivary rinse from head and neck squamous cell carcinoma patients.
    Rettori MM; de Carvalho AC; Bomfim Longo AL; de Oliveira CZ; Kowalski LP; Carvalho AL; Vettore AL
    Carcinogenesis; 2013 Jan; 34(1):20-7. PubMed ID: 23042095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KIF1A and EDNRB are differentially methylated in primary HNSCC and salivary rinses.
    Demokan S; Chang X; Chuang A; Mydlarz WK; Kaur J; Huang P; Khan Z; Khan T; Ostrow KL; Brait M; Hoque MO; Liegeois NJ; Sidransky D; Koch W; Califano JA
    Int J Cancer; 2010 Nov; 127(10):2351-9. PubMed ID: 20162572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma.
    Misawa K; Misawa Y; Kondo H; Mochizuki D; Imai A; Fukushima H; Uehara T; Kanazawa T; Mineta H
    PLoS One; 2015; 10(3):e0118588. PubMed ID: 25734919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.
    Misawa K; Mochizuki D; Imai A; Endo S; Mima M; Misawa Y; Kanazawa T; Carey TE; Mineta H
    Oncotarget; 2016 May; 7(18):26087-98. PubMed ID: 27027429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
    Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Association and Clinical Significance of CDKN2A Promoter Methylation in Head and Neck Squamous Cell Carcinoma: a Meta-Analysis.
    Zhou C; Shen Z; Ye D; Li Q; Deng H; Liu H; Li J
    Cell Physiol Biochem; 2018; 50(3):868-882. PubMed ID: 30355925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positive correlation of tissue inhibitor of metalloproteinase-3 and death-associated protein kinase hypermethylation in head and neck squamous cell carcinoma.
    Nayak CS; Carvalho AL; Jeronimo C; Henrique R; Kim MM; Hoque MO; Chang S; Jiang WW; Koch W; Westra W; Sidransky D; Califano J
    Laryngoscope; 2007 Aug; 117(8):1376-80. PubMed ID: 17592394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.
    Virani S; Bellile E; Bradford CR; Carey TE; Chepeha DB; Colacino JA; Helman JI; McHugh JB; Peterson LA; Sartor MA; Taylor JM; Walline HM; Wolf GT; Rozek LS
    BMC Cancer; 2015 Oct; 15():825. PubMed ID: 26518708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylated genomic loci encoding microRNA as a biomarker panel in tissue and saliva for head and neck squamous cell carcinoma.
    Cao Y; Green K; Quattlebaum S; Milam B; Lu L; Gao D; He H; Li N; Gao L; Hall F; Whinery M; Handley E; Ma Y; Xu T; Jin F; Xiao J; Wei M; Smith D; Bornstein S; Gross N; Pyeon D; Song J; Lu SL
    Clin Epigenetics; 2018; 10():43. PubMed ID: 29636832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer.
    Demokan S; Chuang AY; Pattani KM; Sidransky D; Koch W; Califano JA
    Oncol Rep; 2014 Feb; 31(2):1014-20. PubMed ID: 24337411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only.
    De Schutter H; Geeraerts H; Verbeken E; Nuyts S
    Oncol Rep; 2009 Feb; 21(2):507-13. PubMed ID: 19148529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.
    Misawa K; Mochizuki D; Endo S; Mima M; Misawa Y; Imai A; Shinmura K; Kanazawa T; Carey TE; Mineta H
    Mol Carcinog; 2017 Mar; 56(3):1107-1116. PubMed ID: 27685843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.
    Misawa Y; Misawa K; Kanazawa T; Uehara T; Endo S; Mochizuki D; Yamatodani T; Carey TE; Mineta H
    Cancer; 2014 Jan; 120(2):205-13. PubMed ID: 24122450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein expression and promoter methylation of the candidate biomarker TCF21 in head and neck squamous cell carcinoma.
    Weiss D; Stockmann C; Schrödter K; Rudack C
    Cell Oncol (Dordr); 2013 Jun; 36(3):213-24. PubMed ID: 23529585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.
    Misawa K; Misawa Y; Kanazawa T; Mochizuki D; Imai A; Endo S; Carey TE; Mineta H
    Clin Exp Metastasis; 2016 Feb; 33(2):187-95. PubMed ID: 26572146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene.
    Tawfik HM; El-Maqsoud NM; Hak BH; El-Sherbiny YM
    Am J Otolaryngol; 2011; 32(6):528-36. PubMed ID: 21353335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.